CN113693225A - Ovalbumin-ferulic acid-polysaccharide compound emulsion as well as preparation method and application thereof - Google Patents

Ovalbumin-ferulic acid-polysaccharide compound emulsion as well as preparation method and application thereof Download PDF

Info

Publication number
CN113693225A
CN113693225A CN202110899371.8A CN202110899371A CN113693225A CN 113693225 A CN113693225 A CN 113693225A CN 202110899371 A CN202110899371 A CN 202110899371A CN 113693225 A CN113693225 A CN 113693225A
Authority
CN
China
Prior art keywords
ovalbumin
ferulic acid
polysaccharide
solution
stirring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110899371.8A
Other languages
Chinese (zh)
Other versions
CN113693225B (en
Inventor
苏东晓
黄贞贞
杨欣禧
梁思月
陈乐祺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou University
Original Assignee
Guangzhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou University filed Critical Guangzhou University
Priority to CN202110899371.8A priority Critical patent/CN113693225B/en
Publication of CN113693225A publication Critical patent/CN113693225A/en
Application granted granted Critical
Publication of CN113693225B publication Critical patent/CN113693225B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/045—Organic compounds containing nitrogen as heteroatom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A23L29/04—Fatty acids or derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/733—Alginic acid; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use

Abstract

The invention discloses an ovalbumin-ferulic acid-polysaccharide compound emulsion as well as a preparation method and application thereof. The method comprises the following steps: (1) adding ovalbumin into water to fully hydrate the protein to obtain an ovalbumin dispersion liquid; (2) adding ferulic acid into water to obtain ferulic acid solution; (3) adding ferulic acid solution into the ovalbumin dispersion liquid to obtain ovalbumin-ferulic acid solution; (4) adding polysaccharide into water to obtain polysaccharide solution; (5) adding the ovalbumin-ferulic acid solution into the polysaccharide solution to obtain an ovalbumin-ferulic acid-polysaccharide compound solution; (6) and dropwise adding the medium-chain triglyceride into the ovalbumin-ferulic acid-polysaccharide compound solution to obtain the ovalbumin-ferulic acid-polysaccharide compound emulsion. The compound emulsion has the characteristics of good viscoelasticity and storage stability and high embedding rate, and can be used as a carrier for conveying fat-soluble substances.

Description

Ovalbumin-ferulic acid-polysaccharide compound emulsion as well as preparation method and application thereof
Technical Field
The invention relates to the technical field of food processing, in particular to ovalbumin-ferulic acid-polysaccharide compound emulsion and a preparation method and application thereof.
Background
Ovalbumin (OVA) is the most abundant protein in egg white, has excellent emulsification and gelling properties, and is widely used for preparing nanoparticles or nano-emulsions. Some researches show that Ferulic Acid (FA) is a cross-linking agent of ovalbumin, and the production of an ovalbumin coupling ferulic acid reagent is already carried out, but the reagent is formed by utilizing the two to be chemically cross-linked, and the process is more complex. In addition, it has been reported that the stability of emulsions is improved by using a polyphenol-protein interfacial layer formed by competitive adsorption of natural polyphenols. However, the complexation of polyphenols with proteins may affect the availability of certain amino acids, and may also alter the structure of the proteins, thereby affecting the functionality of the proteins, and complex-stabilized emulsions may also have a significant impact on environmental changes. Therefore, there is a need to develop an effective preparation which is natural and healthy and has good stability and can be used for health products, cosmetics or functional foods.
Proteins and Polysaccharides (PS) form polymers through electrostatic, hydrophobic and hydrogen bonding interactions, while aggregating polysaccharides can stabilize emulsions by attaching to emulsion droplets, thereby controlling colloidal interactions, increasing viscosity to reduce droplet aggregation, or creating yield stress to the motion of stationary particles. Researchers find that an antibacterial film (CN 103554532) with good barrier property and high mechanical strength can be prepared by utilizing collagen-ferulic acid and sodium alginate, and also find that the rheological behavior of the emulsion can be obviously changed by adding polysaccharide, and the antibacterial film plays a key role in adsorbing proteins from a bulk phase to an interface. However, under high shear conditions, the structure of the emulsion prepared from the protein-polysaccharide complex is disrupted, resulting in severe instability of the emulsion.
At present, researches show that hydrogen bonds are formed between hydroxyl groups of polyphenol and oxygen atoms of glycosidic bonds of polysaccharide, non-covalent bonds can be formed between phenolic acid and polysaccharide, different polysaccharides can influence the interactions by protecting or destroying charges, and even can be used as additives for stabilizing colloidal solutions. However, no report on the enhancement of ovalbumin-ferulic acid (OVA-FA) emulsions by polysaccharides has been disclosed. The invention expands the application of eggs to a certain extent, expands the cognition of people on the efficacy of the ovalbumin-ferulic acid nanoparticles, solves the problem of poor storage stability of the emulsion and increases the social and economic values.
Disclosure of Invention
The invention aims to overcome the defects in the prior art and provide a preparation method of an ovalbumin-ferulic acid-polysaccharide compound emulsion.
The invention also aims to provide the ovalbumin-ferulic acid-polysaccharide complex emulsion prepared by the method.
Still another object of the present invention is to provide the use of the ovalbumin-ferulic acid-polysaccharide complex emulsion.
The purpose of the invention is realized by the following technical scheme:
a method for preparing ovalbumin-ferulic acid-polysaccharide compound emulsion comprises the following steps:
(1) adding ovalbumin into water, stirring uniformly, adjusting the pH value to 7.0 +/-0.1, and then standing to fully hydrate the protein to obtain an ovalbumin dispersion liquid;
(2) adding ferulic acid into water, stirring, and adjusting pH to 7.0 + -0.1 to obtain ferulic acid solution;
(3) adding the ferulic acid solution obtained in the step (2) into the ovalbumin dispersion liquid obtained in the step (1), stirring and mixing uniformly, and adjusting the pH value to 6.0 +/-0.1 to obtain an ovalbumin-ferulic acid solution;
(4) adding Polysaccharide (PS) into water, stirring uniformly, and adjusting the pH value to 6.0 +/-0.1 to obtain a polysaccharide solution; wherein the polysaccharide is at least one of Sodium Alginate (SA), carrageenan (KC), Hyaluronic Acid (HA) and Agar;
(5) adding the ovalbumin-ferulic acid solution obtained in the step (3) into the polysaccharide solution obtained in the step (4), and stirring and mixing uniformly to obtain an ovalbumin-ferulic acid-polysaccharide compound solution;
(6) and (3) dropwise adding medium-chain triglyceride (MCT) into the ovalbumin-ferulic acid-polysaccharide compound solution obtained in the step (5), stirring and mixing uniformly, and homogenizing to obtain the ovalbumin-ferulic acid-polysaccharide compound emulsion.
The conditions for fully hydrating the protein by standing in the step (1) are as follows: standing at the low temperature of 4 ℃ for 12-24 hours; preferably: standing at 4 deg.C for 24 hr.
The water used in steps (1), (2) and (4) is preferably deionized water.
The stirring conditions in the steps (1), (2) and (4) are as follows: stirring at room temperature for more than 2 h.
The regulator for regulating the pH value in the steps (1), (2), (3) and (4) is preferably 0.1-1 mol/L HCl solution and 0.1-1 mol/L NaOH solution.
The mass concentration of the egg white protein dispersion liquid in the step (1) is 0.1-20%; preferably 1%.
The mass concentration of the ferulic acid solution in the step (2) is 0.01-10%; preferably 0.5%.
The volume ratio of the egg white protein dispersion liquid to the ferulic acid solution in the step (3) is 4: 1.
The stirring conditions in the step (3) are as follows: stirring at 500-1400 rpm for 30-120 min; preferably: stirring at 800-1400 rpm for 60-120 min.
The polysaccharide in the step (4) is preferably at least one of Sodium Alginate (SA) and carrageenan (KC); more preferably carrageenan (KC).
The mass concentration of the polysaccharide solution in the step (4) is 0.01-10%; further preferably 0.2 to 10%; still more preferably 0.5% to 10%; still more preferably 0.5%.
The volume ratio of the ovalbumin-ferulic acid solution to the polysaccharide solution in the step (5) is 1-12: 1-8; preferably 1-12: 1; more preferably 1: 1.
The stirring conditions in the step (5) are as follows: stirring at 400-1200 rpm for 10-120 min; preferably: stirring at 500-1200 rpm for 30-120 min.
The volume ratio of the ovalbumin-ferulic acid-polysaccharide complex solution to the medium-chain triglyceride (MCT) in the step (6) is 5: 1-15; preferably 5: 5-9; more preferably 5:7 to 9.
The stirring conditions in the step (6) are as follows: stirring at 200-1500 rpm for 10-100 min; preferably 600rpm to 1200rpm for 30min to 60 min.
The homogenization conditions in the step (6) are as follows: homogenizing at 2000-20000 rpm for 1-20 min; preferably: homogenizing at 6000-16000 rpm for 1-10 min; more preferably: homogenizing at 12000rpm for 2 min.
An ovalbumin-ferulic acid-polysaccharide complex emulsion prepared by any one of the methods described above.
The particle size of the ovalbumin-ferulic acid-polysaccharide composite emulsion is 1 um-10 um (determined by Dynamic Light Scattering (DLS)).
The ovalbumin-ferulic acid-polysaccharide complex emulsion is applied to the fields of food, medicines, health products or cosmetics.
The application of the ovalbumin-ferulic acid-polysaccharide complex emulsion in preparing a drug delivery system.
The ovalbumin-ferulic acid-polysaccharide complex emulsion can be used for transmitting fat-soluble polyphenol compounds, fat-soluble vitamin substances, fat-soluble medicines and medicines which interact with protein and/or polyphenol.
A preparation method of drug-loaded ovalbumin-ferulic acid-polysaccharide complex emulsion comprises the steps (1) to (5) of the preparation method of the ovalbumin-ferulic acid-polysaccharide complex emulsion, and the following steps:
(6) adding the medicine into Medium Chain Triglyceride (MCT), stirring and mixing uniformly to obtain medicine-loaded medium chain triglyceride;
(7) and (3) dropwise adding the drug-loaded medium-chain triglyceride obtained in the step (6) into the ovalbumin-ferulic acid-polysaccharide compound solution obtained in the step (5), stirring, mixing uniformly and homogenizing to obtain the drug-loaded ovalbumin-ferulic acid-polysaccharide compound emulsion.
The medicine in the step (6) is at least one of fat-soluble polyphenol compounds, fat-soluble vitamin substances and fat-soluble medicines; rutin is preferred.
The dosage of the medicine in the step (6) is calculated according to a proportion of 85-90 mL of medium chain triglyceride per gram of medicine; preferably 87.5mL of medium chain triglycerides per gram of drug.
The volume ratio of the ovalbumin-ferulic acid-polysaccharide complex solution to the drug-loaded Medium Chain Triglyceride (MCT) in the step (7) is 5: 5-9; more preferably 5: 7-9; more preferably 5: 9.
compared with the prior art, the invention has the following advantages and effects:
(1) the ovalbumin-ferulic acid of the invention forms stable nano particles by utilizing hydrophobic bonds and hydrogen bonds between the two, then strengthens the structure of the ovalbumin-ferulic acid emulsion by polysaccharide, regulates and controls the reaction between an ovalbumin-ferulic acid complex and the polysaccharide by changing the mixing proportion, and obtains the ovalbumin-ferulic acid-polysaccharide emulsion with viscoelasticity and good stability by regulating the mixing proportion of the ovalbumin-ferulic acid-polysaccharide complex and medium-chain triglyceride; in addition, when OVA-FA-polysaccharide and triglyceride are mixed in a volume ratio of 5:9 to prepare the emulsion, only 5mL (with the mass of 0.035g) of OVA-FA-polysaccharide is needed to embed 9mL (namely 9g) of triglyceride, namely the ovalbumin-ferulic acid-polysaccharide emulsion also has the characteristic of high embedding rate.
(2) The raw materials adopted in the process of the invention are all natural biological macromolecules, can be degraded, are cheap and easily obtained, have mild preparation process, no toxic or harmful reagent, easily controlled reaction process, short production period and low equipment investment and production cost, and can be used in a plurality of fields of food, health care products, cosmetics and the like.
(3) The ovalbumin-ferulic acid-polysaccharide compound stable emulsion prepared by the invention has good viscoelasticity and storage stability, and compared with the ovalbumin-ferulic acid nanoparticle stable emulsion, the problem of poor effect of the ovalbumin-ferulic acid nanoparticle stable emulsion is obviously improved by adding the polysaccharide, and the layering phenomenon is avoided.
(4) The ovalbumin-ferulic acid-polysaccharide emulsion prepared by the invention can not only transmit fat-soluble polyphenol compounds, fat-soluble vitamin substances and the like, but also transmit fat-soluble medicines or medicines interacted with protein and polyphenol, thereby realizing the common transmission of a plurality of medicines.
Drawings
FIG. 1 is a graph showing the light transmittance of an ovalbumin-ferulic acid composite solution obtained when the mass concentration of ovalbumin-ferulic acid is 1% and the mass concentration of polysaccharide is 0.5%, both are at pH6.0 + -0.1, and the mixing ratio is 12:1-1:8 (in the graph, OVA: ovalbumin, FA: ferulic acid, PS: polysaccharide, SA: sodium alginate, KC: carrageenan, HA: hyaluronic acid, Agar: Agar).
FIG. 2 is a UV spectrum of the ovalbumin-ferulic acid polysaccharide composite solution obtained when the mass concentration of ovalbumin-ferulic acid is 1% and the mass concentration of polysaccharide is 0.5%, both of which are at pH6.0 +/-0.1, and the mixing ratio is (12:1) - (1: 8); wherein A is Sodium Alginate (SA); b is carrageenan (KC); c is Agar (Agar); d is Hyaluronic Acid (HA).
FIG. 3 is an infrared spectrum of an ovalbumin-ferulic acid polysaccharide composite solution obtained when the mass concentration of ovalbumin-ferulic acid is 1% and the mass concentration of polysaccharide is 0.5%, both of which are at pH6.0 +/-0.1, and the mixing ratio is (12:1) - (1: 8).
FIG. 4 is an appearance diagram showing the mixing ratio of the ovalbumin-ferulic acid to the medium-chain triglyceride in the volume ratio of (5:1) to (5:15) when the ovalbumin-ferulic acid mass concentration is 1% and the polysaccharide mass concentration is 0.5%, both of which are at pH6.0 + -0.1, and the mixing ratio is 1: 1.
FIG. 5 is a rheological diagram showing the mixing ratio of ovalbumin-ferulic acid to medium-chain triglyceride in the volume ratio of (5:5) to (5:9) when the mass concentration of ovalbumin-ferulic acid is 1% and the mass concentration of polysaccharide is 0.5%, both of which are at pH6.0 + -0.1, and the mixing ratio is 1: 1.
FIG. 6 is a microstructure diagram of an ovalbumin-ferulic acid complex solution mixed with medium-chain triglyceride at a volume ratio of (5:7) to (5:9) obtained when the ovalbumin-ferulic acid mass concentration is 1% and the polysaccharide mass concentration is 0.5%, both of which are at pH6.0 + -0.1, and the mixing ratio is 1: 1.
FIG. 7 is a graph of the change in volume ratio of 5:7 and 5:9 of OVA-FA-SA and OVA-FA-KC in stable emulsions during 14 days of storage at 37 ℃; wherein A is an appearance diagram of the emulsion; b is a graph of the particle size of the emulsion; c is an absolute value diagram of the emulsion potential.
FIG. 8 is a rheological diagram showing the mixing ratio of 5:9 by volume of an ovalbumin-ferulic acid composite solution with rutin-loaded medium-chain triglyceride when the mass concentration of the ovalbumin-ferulic acid is 1% and the mass concentration of polysaccharide is 0.5%, both of which are at pH6.0 + -0.1, and the mixing ratio is 1: 1; wherein A is storage modulus (also called elastic modulus; G'); b is loss modulus (also known as viscous modulus; G').
Detailed Description
The present invention will be described in further detail with reference to examples, but the embodiments of the present invention are not limited thereto. Reagents, methods and apparatus used in the present invention are conventional in the art unless otherwise indicated. The test methods in the following examples, in which specific experimental conditions are not specified, are generally performed according to conventional experimental conditions or according to the experimental conditions recommended by the manufacturer. Unless otherwise specified, reagents and starting materials for use in the present invention are commercially available.
The acid-base solution for adjusting the pH value is a pH value adjusting agent which is conventional in the field, such as 0.1mol/L to 1mol/L hydrochloric acid, sodium hydroxide and the like.
The invention relates to an egg white protein (biotechnology grade) and ferulic acid which are purchased from Shanghai Meclin Biotechnology limited (China, Shanghai); sodium alginate, carrageenan, hyaluronic acid, agar and medium chain triglyceride are purchased from Shanghai-derived leaf Biotech limited, China, Shanghai.
Example 1
(1) Accurately weighing 2g of Ovalbumin (OVA) powder, dispersing the powder in 200g of deionized water, continuously stirring for 2h at room temperature, adjusting the pH to 7.0 +/-0.1 by using acid-alkali solution, and then placing at 4 ℃ for 24h to fully hydrate the protein so as to obtain an ovalbumin stock solution with the mass concentration of 1%.
(2) Weighing 1g of Ferulic Acid (FA) powder, adding into 200g of deionized water, continuously stirring for 2h at room temperature, adjusting the pH to 7.0 +/-0.1 with alkali liquor, and fully and uniformly mixing ferulic acid to obtain a ferulic acid solution with the mass concentration of 0.5%.
(3) Mixing the ovalbumin solution obtained in the step (1) and the ferulic acid solution obtained in the step (2) according to a volume ratio of 4:1, namely dropwise adding the ferulic acid solution into the ovalbumin solution under magnetic stirring, wherein the magnetic stirring speed is 800-1400 rpm, the stirring time is 60-120 min, and adjusting the pH of the ovalbumin-ferulic acid mixed solution to 6.0 +/-0.1 to obtain the ovalbumin-ferulic acid nanoparticle solution.
(4) Weighing 1g of Sodium Alginate (SA), carrageenan (KC), Hyaluronic Acid (HA) and Agar (Agar) powder respectively, adding the powder into 200g of deionized water, continuously stirring for 2 hours at room temperature, adjusting the pH to 6.0 +/-0.1 by using an alkali solution, and fully and uniformly mixing polysaccharides to obtain a polysaccharide solution with the mass concentration of 0.5%.
(5) And (3) mixing the ovalbumin-ferulic acid nanoparticle solution (OVA-FA) obtained in the step (3) and the Polysaccharide Solution (PS) obtained in the step (4) according to the volume ratio of 12:1, 8:1, 4:1, 1:4 and 1:8 respectively, namely, dropwise adding the polysaccharide solution into the ovalbumin-ferulic acid nanoparticle solution respectively under magnetic stirring, wherein the magnetic stirring speed is 400-1200 rpm, and the stirring time is 30-120 min, so as to obtain the ovalbumin-ferulic acid-polysaccharide complex solution.
This example examined the change in light transmittance of ovalbumin-ferulic acid nanoparticle solutions and polysaccharide solutions mixed at different volume ratios. The light transmittance and ultraviolet spectrum of the ovalbumin-ferulic acid-polysaccharide composite solution with different volume ratios are respectively shown in figure 1 and figure 2:
when the mixing ratio of the sodium alginate, the carrageenan and the hyaluronic acid to the ovalbumin-polyphenol (ferulic acid) composite liquid is more than 1:1, the light transmittance of the formed solution is reduced along with the increase of the ratio of the ovalbumin-polyphenol composite liquid, and the trend is similar to that of the ovalbumin-polyphenol composite liquid. However, the light transmittance of the OVA-FA-polysaccharide complex solution (OVA-FA-SA, OVA-FA-KC, OVA-FA-HA and OVA-FA-Agar) is always lower than that of the ovalbumin-polyphenol complex solution, which indicates that the polysaccharide and the ovalbumin-polyphenol complex solution interact to form a complex. The low light transmittance was attributed to the formation of aggregates between the protein and polysaccharide, and when the light transmittance reached a minimum, it was indicated that OVA-FA was saturated in complexing with the polysaccharide. Therefore, the optimal mixing ratio of polysaccharide complexed with OVA-FA was 1:1 (FIG. 1).
Different mixing volume ratios of polysaccharide to OVA-FA have different effects on the UV spectrum of OVA. As the addition ratio of the polysaccharide is increased, the absorption peaks of OVA-FA are sequentially reduced. This is probably due to structural changes in the interaction of the protein with the polysaccharide, by exposing the heteroaromatic hydrophobic groups in the tryptophan and tyrosine residues, which in turn alters the conformation of the protein molecule, resulting in a reduction in the protein absorption peak (FIG. 2).
Example 2
(1) Accurately weighing 2g of Ovalbumin (OVA) powder, dispersing the powder in 200g of deionized water, continuously stirring for 2h at room temperature, adjusting the pH to 7.0 +/-0.1 by using acid-alkali solution, and then placing at 4 ℃ for 24h to fully hydrate the protein so as to obtain an ovalbumin stock solution with the mass concentration of 1%.
(2) Weighing 1g of Ferulic Acid (FA) powder, adding into 200g of deionized water, continuously stirring for 2h at room temperature, adjusting the pH to 7.0 +/-0.1 with alkali liquor, and fully and uniformly mixing ferulic acid to obtain a ferulic acid solution with the mass concentration of 0.5%.
(3) Mixing the ovalbumin solution obtained in the step (1) and the ferulic acid solution obtained in the step (2) according to a volume ratio of 4:1, namely dropwise adding the ferulic acid solution into the ovalbumin solution under magnetic stirring, wherein the magnetic stirring speed is 800-1400 rpm, the stirring time is 60-120 min, and adjusting the pH of the ovalbumin-ferulic acid mixed solution to 6.0 +/-0.1 to obtain the ovalbumin-ferulic acid nanoparticle solution.
(4) Respectively weighing 1g of Sodium Alginate (SA), carrageenan (KC), Hyaluronic Acid (HA) and Agar (Agar) powder, adding into 200g of deionized water, continuously stirring for 2h at room temperature, adjusting the pH to 6.0 +/-0.1 with an alkali solution, and fully and uniformly mixing polysaccharides to obtain a polysaccharide solution with the mass concentration of 0.5%.
(5) And (3) mixing the ovalbumin-ferulic acid nanoparticle solution obtained in the step (3) with the polysaccharide solution obtained in the step (4) according to a volume ratio of 1:1, namely, dropwise adding the polysaccharide solution into the ovalbumin-ferulic acid nanoparticle solution under magnetic stirring at a magnetic stirring speed of 400-1200 rpm for 30-120 min to obtain the ovalbumin-ferulic acid-polysaccharide compound solution.
This example examined the change in the infrared spectrum of an ovalbumin-ferulic acid-polysaccharide complex solution. The infrared spectrum of the ovalbumin-ferulic acid-polysaccharide complex solution is shown in figure 3. FIG. 3 shows the respective IR amide I-band Gaussian fits of OVA, OVA-FA-SA, OVA-FA-KC, OVA-FA-Agar and OVA-FA-HA complexes. The secondary structure of the protein was calculated using different regions of the amide I band. Addition of ferulic acid resulted in an increase in the alpha-helix (alpha-helix) and beta-sheet (beta-sheet) content of OVA, and a decrease in the beta-turn (beta-turn) and random coil (random coil) content. This may be due primarily to the interaction of ferulic acid with OVA to form ordered hydrogen bonds. However, the addition of polysaccharide to the OVA-FA complex resulted in a significant decrease in alpha-helix content, and the addition of polysaccharide to all but agar significantly increased the beta-sheet content. On the one hand, studies have shown that an increase in β -sheet content leads to a decrease in interfacial tension and an increase in emulsion stability, mainly due to the disordered structure leading to a rapid conformational change of the protein at the oil-water interface, exposing hydrophobic amino acids in the internal structure, thereby decreasing interfacial tension and leading to lower equilibrium interfacial tension over time. On the other hand, the beta-sheet favors the formation of hydrogen bonds, while hydrogen-bonded micelles favor the formation of oil-water interface structures, confirming our discovery of the ability of OVA-FA-polysaccharides to stabilize emulsions.
Example 3
(1) Accurately weighing 2g of Ovalbumin (OVA) powder, dispersing the powder in 200g of deionized water, continuously stirring for 2h at room temperature, adjusting the pH to 7.0 +/-0.1 by using acid-alkali solution, and then placing at 4 ℃ for 24h to fully hydrate the protein so as to obtain an ovalbumin stock solution with the mass concentration of 1%.
(2) Weighing 1g of Ferulic Acid (FA) powder, adding into 200g of deionized water, continuously stirring for 2h at room temperature, adjusting the pH to 7.0 +/-0.1 with alkali liquor, and fully and uniformly mixing ferulic acid to obtain a ferulic acid solution with the mass concentration of 0.5%.
(3) Mixing the ovalbumin solution obtained in the step (1) and the ferulic acid solution obtained in the step (2) according to a volume ratio of 4:1, namely dropwise adding the ferulic acid solution into the ovalbumin solution under magnetic stirring, wherein the magnetic stirring speed is 800-1400 rpm, the stirring time is 60-120 min, and adjusting the pH of the ovalbumin-ferulic acid mixed solution to 6.0 +/-0.1 to obtain the ovalbumin-ferulic acid nanoparticle solution.
(4) Weighing 1g of Sodium Alginate (SA), carrageenan (KC), Hyaluronic Acid (HA) and Agar (Agar) powder respectively, adding the powder into 200g of deionized water, continuously stirring for 2 hours at room temperature, adjusting the pH to 6.0 +/-0.1 by using an alkali solution, and fully and uniformly mixing polysaccharides to obtain a polysaccharide solution with the mass concentration of 0.5%.
(5) And (3) respectively mixing the ovalbumin-ferulic acid nanoparticle solution (OVA-FA) obtained in the step (3) with the polysaccharide solution obtained in the step (4) according to the volume ratio of 1:1, namely respectively dropwise adding the polysaccharide solution into the ovalbumin-ferulic acid nanoparticle solution under magnetic stirring, wherein the magnetic stirring speed is 400-1200 rpm, and the stirring time is 30-120 min, so as to obtain the ovalbumin-ferulic acid-polysaccharide composite solution.
(6) And (3) mixing the ovalbumin-ferulic acid-polysaccharide composite solution obtained in the step (5) with medium-chain triglyceride according to the volume ratio of 5:1, 5:3, 5:5, 5:7, 5:9, 5:11, 5:13 and 5:15 respectively, namely dropwise adding medium-chain triglyceride (MCT) into the ovalbumin-ferulic acid-polysaccharide composite solution under magnetic stirring, wherein the magnetic stirring speed is 200-1500 rpm, and the stirring time is 30 min.
(7) Homogenizing the mixed solution obtained in the step (6) at 12000rpm for a certain time (about 2min) to obtain the ovalbumin-ferulic acid-polysaccharide ternary system stable emulsion.
This example examines the volume fraction of oil phase versus the appearance of stable emulsion of ovalbumin-ferulic acid-polysaccharide complex (standing at room temperature for 120min) (OVA-FA emulsion was used as control, i.e. OVA-FA emulsion was prepared directly without addition of polysaccharide solution as described above). The appearance of the ovalbumin-ferulic acid-polysaccharide complex stabilized emulsion is shown in figure 4. It can be seen from fig. 4 that the ovalbumin-ferulic acid nanoparticle stable emulsion HAs poor effect, the emulsion HAs delamination phenomenon under all oil phase volume fractions, compared with the ovalbumin-ferulic acid nanoparticle stable emulsion, after the polysaccharide is added, the emulsion can be better stabilized under a certain oil phase volume fraction, the problem of poor emulsion stabilization effect is still solved by adding the agar, and the obvious delamination phenomenon still appears, and also seen from fig. 4, the emulsion can be better stabilized when the volume ratio of OVA-FA-SA, OVA-FA-KC, OVA-FA-HA and MCT is 5:5, 5:7 and 5: 9.
Example 4
(1) Accurately weighing 2g of Ovalbumin (OVA) powder, dispersing the powder in 200g of deionized water, continuously stirring for 2h at room temperature, adjusting the pH to 7.0 +/-0.1 by using acid-alkali solution, and then placing at 4 ℃ for 24h to fully hydrate the protein so as to obtain an ovalbumin stock solution with the mass concentration of 1%.
(2) Weighing 1g of Ferulic Acid (FA) powder, adding into 200g of deionized water, continuously stirring for 2h at room temperature, adjusting the pH to 7.0 +/-0.1 with alkali liquor, and fully and uniformly mixing ferulic acid to obtain a ferulic acid solution with the mass concentration of 0.5%.
(3) Mixing the ovalbumin solution obtained in the step (1) and the ferulic acid solution obtained in the step (2) according to a volume ratio of 4:1, namely dropwise adding the ferulic acid solution into the ovalbumin solution under magnetic stirring, wherein the magnetic stirring speed is 800-1400 rpm, the stirring time is 60-120 min, and adjusting the pH of the ovalbumin-ferulic acid mixed solution to 6.0 +/-0.1 to obtain the ovalbumin-ferulic acid nanoparticle solution.
(4) Weighing 1g of Sodium Alginate (SA), carrageenan (KC), Hyaluronic Acid (HA) and Agar (Agar) powder respectively, adding the powder into 200g of deionized water, continuously stirring for 2 hours at room temperature, adjusting the pH to 6.0 +/-0.1 by using an alkali solution, and fully and uniformly mixing polysaccharides to obtain a polysaccharide solution with the mass concentration of 0.5%.
(5) And (3) mixing the ovalbumin-ferulic acid nanoparticle solution obtained in the step (3) with the polysaccharide solution obtained in the step (4) according to a volume ratio of 1:1, namely, dropwise adding the polysaccharide solution into the ovalbumin-ferulic acid nanoparticle solution under magnetic stirring at a magnetic stirring speed of 400-1200 rpm for 30-120 min to obtain the ovalbumin-ferulic acid-polysaccharide composite solution.
(6) And (3) mixing the ovalbumin-ferulic acid-polysaccharide composite solution obtained in the step (5) with medium-chain triglyceride according to the volume ratio of 5:5, 5:7 and 5:9 respectively, namely, dropwise adding the medium-chain triglyceride into the ovalbumin-ferulic acid-polysaccharide composite solution under magnetic stirring at the speed of 200-1500 rpm for 30 min.
(7) Homogenizing the mixed solution obtained in the step (6) at 12000rpm for a certain time (about 2min) to obtain the ovalbumin-ferulic acid-polysaccharide ternary system stable emulsion.
This example studies the rheological properties of the emulsion and discusses the effect of different oil phase volume ratios on the mechanical properties of the emulsion. Standing at 4 ℃ for 12h, and then measuring by using a dynamic shear rheometer, wherein the specific measurement steps are as follows: the sample was placed between two parallel plates with the gap height set to 1 mm; performing an amplitude scan to determine a Linear Viscoelastic Region (LVR); at a constant frequency of 1hz, the strain increases logarithmically from 0.1% to 100%; the frequency sweep was from 0.1 to 100rad/s with a fixed strain of 0.5% (within LVR).
The results are shown in FIG. 5: as the frequency is increased, the crossing point of G 'and G' of OVA-FA-HA emulsion appears, which indicates that the frequency is beyond a certain range, the sample structure is irreversibly changed, and the structure of the sample is damaged to a certain degree. However, when the volume ratio of the oil phase of the OVA-FA-sodium alginate or the OVA-FA-carrageenan is 5:7 and 5:9, G 'of the sample is always larger than G' (G 'is storage modulus and is also called elastic modulus, G' is loss modulus and is also called viscous modulus, and viscoelasticity is a general term for G 'and G'), shows main elastic behavior and has good stability. At the same time, at high frequency, no crossing points of G 'and G' of the samples still occurred, indicating that no structural failure occurred at high rate deformation in emulsions stabilized with OVA-FA-SA or OVA-FA-KC at oil phase volume ratios of 5:7 and 5: 9.
Example 5
(1) Accurately weighing 2g of Ovalbumin (OVA) powder, dispersing the powder in 200g of deionized water, continuously stirring for 2h at room temperature, adjusting the pH to 7.0 +/-0.1 by using acid-alkali solution, and then placing at 4 ℃ for 24h to fully hydrate the protein so as to obtain an ovalbumin stock solution with the mass concentration of 1%.
(2) Weighing 1g of Ferulic Acid (FA) powder, adding into 200g of deionized water, continuously stirring for 2h at room temperature, adjusting the pH to 7.0 +/-0.1 with alkali liquor, and fully and uniformly mixing ferulic acid to obtain a ferulic acid solution with the mass concentration of 0.5%.
(3) Mixing the ovalbumin solution obtained in the step (1) and the ferulic acid solution obtained in the step (2) according to a volume ratio of 4:1, namely dropwise adding the ferulic acid solution into the ovalbumin solution under magnetic stirring, wherein the magnetic stirring speed is 800-1400 rpm, the stirring time is 60-120 min, and adjusting the pH of the ovalbumin-ferulic acid mixed solution to 6.0 +/-0.1 to obtain the ovalbumin-ferulic acid nanoparticle solution.
(4) Weighing 1g of Sodium Alginate (SA), carrageenan (KC), Hyaluronic Acid (HA) and Agar (Agar) powder respectively, adding the powder into 200g of deionized water, continuously stirring for 2 hours at room temperature, adjusting the pH to 6.0 +/-0.1 by using an alkali solution, and fully and uniformly mixing polysaccharides to obtain a polysaccharide solution with the mass concentration of 0.5%.
(5) Mixing the ovalbumin-ferulic acid nanoparticle solution (OVA-FA) obtained in the step (3) and the polysaccharide solution obtained in the step (4) according to a volume ratio of 1:1, namely, respectively dropwise adding the polysaccharide solutions into the ovalbumin-ferulic acid nanoparticle solution under magnetic stirring, wherein the magnetic stirring speed is 400-1200 rpm, and the stirring time is 30-120 min, so as to obtain the ovalbumin-ferulic acid-polysaccharide composite solution.
(6) And (3) mixing the ovalbumin-ferulic acid-polysaccharide composite solution obtained in the step (5) with medium-chain triglyceride (MCT) according to the volume ratio of 5:7 and 5:9 respectively, namely, dropwise adding the medium-chain triglyceride into the ovalbumin-ferulic acid-polysaccharide composite solution under magnetic stirring at the speed of 200-1500 rpm for 30 min.
(7) Homogenizing the mixed solution obtained in the step (6) for a certain time (2min) under the condition of 12000rpm to obtain the ovalbumin-ferulic acid-polysaccharide ternary system stable emulsion.
In this example, the microstructure of the OVA-FA-SA or OVA-FA-KC and MCT stabilized emulsion at 5:7 or 5:9 (i.e., OVA-FA-PS: Oil: 5:7 or 5:9) was observed by laser confocal scanning microscope (CLSM), i.e., homogenized, and then placed at 4 ℃ for 12 hours and observed by laser confocal microscope. The results are shown in FIG. 6: the result shows that compared with the emulsion prepared by OVA-SA or OVA-KC (under the same condition, the polysaccharide solution is replaced by distilled water to be used as a contrast), the emulsion stabilized by the OVA-FA-SA or OVA-FA-KC compound has a red film adsorbed around the spherical oil drops, which can effectively prevent the emulsion from aggregating, thereby improving the stability of the emulsion, and the spherical oil drops are more compact; as the volume ratio of the oil phase increases, the gaps between the emulsion droplets gradually decrease and the droplets become more compact. However, by comparing the OVA-FA-SA and OVA-FA-KC with MCT in a 5:9 volume ratio, it was found that the OVA-FA-KC stabilized emulsion was more compact, had smaller droplets, was more uniformly distributed, and had a red film adsorbed around the droplets. Thus, the OVA-FA-KC stabilized emulsion is microscopically more stable than the OVA-FA-SA stabilized emulsion.
Example 6
(1) Accurately weighing 2g of Ovalbumin (OVA) powder, dispersing the powder in 200g of deionized water, continuously stirring for 2h at room temperature, adjusting the pH to 7.0 +/-0.1 by using acid-alkali solution, and then placing at 4 ℃ for 24h to fully hydrate the protein so as to obtain an ovalbumin stock solution with the mass concentration of 1%.
(2) Weighing 1g of Ferulic Acid (FA) powder, adding into 200g of deionized water, continuously stirring for 2h at room temperature, adjusting the pH to 7.0 +/-0.1 with alkali liquor, and fully and uniformly mixing ferulic acid to obtain a ferulic acid solution with the mass concentration of 0.5%.
(3) Mixing the ovalbumin solution obtained in the step (1) and the ferulic acid solution obtained in the step (2) according to a volume ratio of 4:1, dropwise adding the ferulic acid solution into the ovalbumin solution under magnetic stirring, wherein the magnetic stirring speed is 800-1400 rpm, the stirring time is 60-120 min, and adjusting the pH of the ovalbumin-ferulic acid mixed solution to 6.0 +/-0.1 to obtain the ovalbumin-ferulic acid nanoparticle solution.
(4) Weighing 1g of Sodium Alginate (SA), carrageenan (KC), Hyaluronic Acid (HA) and Agar (Agar) powder respectively, adding the powder into 200g of deionized water, continuously stirring for 2 hours at room temperature, adjusting the pH to 6.0 +/-0.1 by using an alkali solution, and fully and uniformly mixing polysaccharides to obtain a polysaccharide solution with the mass concentration of 0.5%.
(5) And (3) mixing the ovalbumin-ferulic acid nanoparticle solution obtained in the step (3) with the polysaccharide solution obtained in the step (4) according to a volume ratio of 1:1, namely, dropwise adding the polysaccharide solution into the ovalbumin-ferulic acid nanoparticle solution under magnetic stirring at a magnetic stirring speed of 400-1200 rpm for 30-120 min to obtain the ovalbumin-ferulic acid-polysaccharide composite solution.
(6) And (3) mixing the ovalbumin-ferulic acid-polysaccharide composite solution obtained in the step (5) with medium-chain triglyceride according to the volume ratio of 5:7 to 5:9, namely, respectively dropwise adding the medium-chain triglyceride into the ovalbumin-ferulic acid-polysaccharide composite solution under magnetic stirring, wherein the magnetic stirring speed is 200-1500 rpm, and the stirring time is 30 min.
(7) Homogenizing the mixed solution obtained in the step (6) for a certain time (2min) under the condition of 12000rpm to obtain the ovalbumin-ferulic acid-polysaccharide ternary system stable emulsion.
(8) The emulsion in step (7) was left at 37 ℃ for two weeks, and the particle size potential of the emulsion (measured by Dynamic Light Scattering (DLS)) was observed and measured.
This example investigates the storage stability of an ovalbumin-ferulic acid-polysaccharide complex stabilized emulsion. FIG. 7 shows the change in volume ratio of 5:7 and 5:9 of OVA-FA-SA and OVA-FA-KC in stable emulsions during 14 days of storage at 37 ℃. For both the OVA-FA-SA and OVA-FA-KC stabilized emulsions, the average particle size increased slightly with increasing storage time and the emulsions remained stable with no significant separation observed at storage 7d (FIG. 7A), indicating that the emulsions exhibited good stability at this storage time, primarily due to increased electrostatic repulsion and steric hindrance between the droplets. After storage for 7 days, the average particle size of the emulsion increased slightly due to electrostatic repulsion. However, as shown in FIG. 7B, the particle size of the OVA-FA-KC stable emulsion is increased remarkably, and FIG. 7A shows that no significant stratification is observed after storage for 14 days, which is probably because the specific surface area of the oil drops is gradually reduced along with the increase of the volume of the oil drops, and the oil drops are covered by the OVA-FA-KC compound, so that the specific surface area of the oil drops is kept stable and no stratification occurs. From FIG. 7C, it can be found that the absolute value of the potential of the emulsion gradually decreased with the increase of the storage time. Thus, it was found that the storage stability of OVA-FA-KC emulsion was better than that of OVA-FA-SA.
Example 7
(1) Accurately weighing 2g of Ovalbumin (OVA) powder, dispersing the powder in 200g of deionized water, continuously stirring for 2h at room temperature, adjusting the pH to 7.0 +/-0.1 by using acid-alkali solution, and then placing at 4 ℃ for 24h to fully hydrate the protein so as to obtain an ovalbumin stock solution with the mass concentration of 1%.
(2) Weighing 1g of Ferulic Acid (FA) powder, adding into 200g of deionized water, continuously stirring for 2h at room temperature, adjusting the pH to 7.0 +/-0.1 with alkali liquor, and fully and uniformly mixing ferulic acid to obtain a ferulic acid solution with the mass concentration of 0.5%.
(3) Mixing the ovalbumin solution obtained in the step (1) and the ferulic acid solution obtained in the step (2) according to a volume ratio of 4:1, dropwise adding the ferulic acid solution into the ovalbumin solution under magnetic stirring, wherein the magnetic stirring speed is 800-1400 rpm, the stirring time is 60-120 min, and adjusting the pH of the ovalbumin-ferulic acid mixed solution to 6.0 +/-0.1 to obtain the ovalbumin-ferulic acid nanoparticle solution.
(4) Respectively weighing 1g of Sodium Alginate (SA), carrageenan (KC) and Hyaluronic Acid (HA), then respectively adding into 200g of deionized water, continuously stirring for 2h at room temperature, adjusting the pH to 6.0 +/-0.1 with alkaline solution, and fully and uniformly mixing the polysaccharides to obtain polysaccharide solution with mass concentration of 0.5%.
(5) And (3) mixing the ovalbumin-ferulic acid nanoparticle solution obtained in the step (3) with the polysaccharide solution obtained in the step (4) according to a volume ratio of 1:1, namely, dropwise adding the polysaccharide solution into the ovalbumin-ferulic acid nanoparticle solution under magnetic stirring at a magnetic stirring speed of 400-1200 rpm for 30-120 min to obtain the ovalbumin-ferulic acid-polysaccharide composite solution.
(6) Weighing 4g of rutin (Ru) powder, adding the rutin (Ru) powder into 350mL of Medium Chain Triglyceride (MCT), continuously stirring for 30-90 min at room temperature, and then centrifuging the rutin (Ru) powder for 2-10 min at the rotating speed of 5000rpm, wherein the supernatant is the rutin-loaded Medium Chain Triglyceride (MCT).
(7) And (3) mixing the ovalbumin-ferulic acid-polysaccharide composite solution obtained in the step (5) with the rutin-loaded medium-chain triglyceride obtained in the step (6) according to a volume ratio of 5:9, namely, respectively dropwise adding the rutin-loaded medium-chain triglyceride into the ovalbumin-ferulic acid-polysaccharide composite solution under magnetic stirring at a speed of 200-1500 rpm for 30 min.
(8) Homogenizing the mixed solution obtained in the step (6) for 2min at 12000rpm to obtain rutin-loaded ovalbumin-ferulic acid-polysaccharide ternary system stable emulsion (OVA-FA-SA-Ru, OVA-FA-KC-Ru and OVA-FA-HA-Ru).
This example examined the effect of the loading of fat-soluble polyphenols on the rheological properties of the emulsions (the emulsions prepared under the same conditions, stabilized by the ternary system without rutin loading, OVA-FA-SA, OVA-FA-KC, OVA-FA-HA were used as controls). The results are shown in FIG. 8: as can be seen from the figure, the storage modulus and loss modulus of OVA-FA-SA-Ru and OVA-FA-KC-Ru are significantly higher than those of OVA-FA-SA and OVA-FA-KC. The result shows that the storage modulus and the loss modulus of the ternary emulsion can be increased by the loading of the fat-soluble polyphenol. The storage modulus and loss modulus of the emulsion of the OVA-FA-HA loaded fat-soluble polyphenol are obviously lower than those of OVA-FA-SA and OVA-FA-KC loaded fat-soluble polyphenol emulsions although the storage modulus and loss modulus of the emulsion are increased relative to the OVA-FA-HA emulsion alone. After the OVA-FA-SA and the OVA-FA-KC are loaded by fat-soluble polyphenol, the storage modulus and the loss modulus of the OVA-FA-SA and the OVA-FA-KC are obviously improved compared with those of the independent OVA-FA-SA and OVA-FA-KC, and the OVA-FA-SA and the OVA-FA-KC do not show larger difference, but show larger difference with the OVA-FA-HA. Furthermore, during the increase in the frequency of testing, the G' of each emulsion was significantly higher than G ", which is indicative of the solid nature of the gel.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.

Claims (10)

1. A preparation method of ovalbumin-ferulic acid-polysaccharide compound emulsion is characterized by comprising the following steps:
(1) adding ovalbumin into water, stirring uniformly, adjusting the pH value to 7.0 +/-0.1, and then standing to fully hydrate the protein to obtain an ovalbumin dispersion liquid;
(2) adding ferulic acid into water, stirring, and adjusting pH to 7.0 + -0.1 to obtain ferulic acid solution;
(3) adding the ferulic acid solution obtained in the step (2) into the ovalbumin dispersion liquid obtained in the step (1), stirring and mixing uniformly, and adjusting the pH value to 6.0 +/-0.1 to obtain an ovalbumin-ferulic acid solution;
(4) adding polysaccharide into water, stirring uniformly, and adjusting the pH value to 6.0 +/-0.1 to obtain a polysaccharide solution; wherein the polysaccharide is at least one of sodium alginate, carrageenan, hyaluronic acid and agar;
(5) adding the ovalbumin-ferulic acid solution obtained in the step (3) into the polysaccharide solution obtained in the step (4), and stirring and mixing uniformly to obtain an ovalbumin-ferulic acid-polysaccharide compound solution;
(6) and (3) dropwise adding the medium-chain triglyceride into the ovalbumin-ferulic acid-polysaccharide compound solution obtained in the step (5), stirring and mixing uniformly, and homogenizing to obtain the ovalbumin-ferulic acid-polysaccharide compound emulsion.
2. The method for preparing an ovalbumin-ferulic acid-polysaccharide complex emulsion according to claim 1, wherein:
the mass concentration of the egg white protein dispersion liquid in the step (1) is 0.1-20%;
the mass concentration of the ferulic acid solution in the step (2) is 0.01-10%;
the volume ratio of the egg white protein dispersion liquid to the ferulic acid solution in the step (3) is 4: 1;
the mass concentration of the polysaccharide solution in the step (4) is 0.01-10%;
the volume ratio of the ovalbumin-ferulic acid solution to the polysaccharide solution in the step (5) is 1-12: 1-8;
the volume ratio of the ovalbumin-ferulic acid-polysaccharide complex solution to the medium-chain triglyceride in the step (6) is 5:1 to 15.
3. The method for preparing an ovalbumin-ferulic acid-polysaccharide complex emulsion according to claim 2, wherein:
the mass concentration of the egg white protein dispersion liquid in the step (1) is 1%;
the mass concentration of the ferulic acid solution in the step (2) is 0.5 percent;
the mass concentration of the polysaccharide solution in the step (4) is 0.2-10%;
the volume ratio of the ovalbumin-ferulic acid solution to the polysaccharide solution in the step (5) is 1-12: 1;
the volume ratio of the ovalbumin-ferulic acid-polysaccharide complex solution to the medium-chain triglyceride in the step (6) is 5:5 to 9.
4. The method for preparing an ovalbumin-ferulic acid-polysaccharide complex emulsion according to claim 3, wherein:
the volume ratio of the ovalbumin-ferulic acid solution to the polysaccharide solution in the step (5) is 1: 1;
the volume ratio of the ovalbumin-ferulic acid-polysaccharide complex solution to the medium-chain triglyceride in the step (6) is 5:7 to 9.
5. The method for preparing an ovalbumin-ferulic acid-polysaccharide complex emulsion according to claim 1, wherein:
the conditions for fully hydrating the protein by standing in the step (1) are as follows: standing at the low temperature of 4 ℃ for 12-24 hours;
the stirring conditions in the steps (1), (2) and (4) are as follows: continuously stirring for more than 2h at room temperature;
the regulators used for regulating the pH value in the steps (1), (2), (3) and (4) are 0.1-1 mol/L HCl solution and 0.1-1 mol/L NaOH solution;
the stirring conditions in the step (3) are as follows: stirring at 500-1400 rpm for 30-120 min;
the stirring conditions in the step (5) are as follows: stirring at 400-1200 rpm for 10-120 min;
the stirring conditions in the step (6) are as follows: stirring at 200-1500 rpm for 10-100 min;
the homogenization conditions in the step (6) are as follows: homogenizing at 2000-20000 rpm for 1-20 min.
6. An ovalbumin-ferulic acid-polysaccharide complex emulsion, which is characterized in that: prepared by the method of any one of claims 1 to 5.
7. Use of the ovalbumin-ferulic acid-polysaccharide complex emulsion of claim 6 in the field of food, pharmaceutical, nutraceutical or cosmetic products.
8. Use of the ovalbumin-ferulic acid-polysaccharide complex emulsion of claim 6 for the preparation of a drug delivery system.
9. A preparation method of drug-loaded ovalbumin-ferulic acid-polysaccharide complex emulsion is characterized by comprising the following steps: the method for preparing an ovalbumin-ferulic acid-polysaccharide complex emulsion, which comprises the steps (1) to (5) of the method for preparing an ovalbumin-ferulic acid-polysaccharide complex emulsion according to any one of claims 1 to 5, and comprises the following steps:
(6) adding the drug into the medium chain triglyceride, and stirring and mixing uniformly to obtain the drug-loaded medium chain triglyceride;
(7) and (3) dropwise adding the drug-loaded medium-chain triglyceride obtained in the step (6) into the ovalbumin-ferulic acid-polysaccharide compound solution obtained in the step (5), stirring, mixing uniformly and homogenizing to obtain the drug-loaded ovalbumin-ferulic acid-polysaccharide compound emulsion.
10. The method of preparing a drug-loaded ovalbumin-ferulic acid-polysaccharide complex emulsion of claim 9, wherein the method comprises the steps of:
the medicine in the step (6) is at least one of fat-soluble polyphenol compounds, fat-soluble vitamin substances and fat-soluble medicines;
the dosage of the medicine in the step (6) is calculated according to a proportion of 85-90 mL of medium chain triglyceride per gram of medicine;
the volume ratio of the ovalbumin-ferulic acid-polysaccharide complex solution to the drug-loaded medium-chain triglyceride in the step (7) is 5:5 to 9.
CN202110899371.8A 2021-08-06 2021-08-06 Ovalbumin-ferulic acid-polysaccharide compound emulsion and preparation method and application thereof Active CN113693225B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110899371.8A CN113693225B (en) 2021-08-06 2021-08-06 Ovalbumin-ferulic acid-polysaccharide compound emulsion and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110899371.8A CN113693225B (en) 2021-08-06 2021-08-06 Ovalbumin-ferulic acid-polysaccharide compound emulsion and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN113693225A true CN113693225A (en) 2021-11-26
CN113693225B CN113693225B (en) 2023-12-08

Family

ID=78652150

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110899371.8A Active CN113693225B (en) 2021-08-06 2021-08-06 Ovalbumin-ferulic acid-polysaccharide compound emulsion and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN113693225B (en)

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005158B1 (en) * 2003-06-30 2006-02-28 University Of Florida Research Foundation, Inc. Methods of improving the properties of egg proteins
US20160038428A1 (en) * 2014-08-05 2016-02-11 Advanced Bionutrition Corp. Encapsulation of hydrophobic biologically active compounds
JP2016037461A (en) * 2014-08-06 2016-03-22 ユーハ味覚糖株式会社 Production method of nanoparticle which uses naturally occurring component as substrate
CN105601701A (en) * 2016-01-21 2016-05-25 中国农业大学 Protein-polyphenol covalent compound and preparation method and application thereof
US20180134757A1 (en) * 2015-04-24 2018-05-17 Colgate-Palmolive Company Porous protein particles as carriers for actives
CN108719999A (en) * 2018-05-07 2018-11-02 中国农业大学 A kind of preparation method and applications of protein-polyphenol-polysaccharide covalent compound
CN108783149A (en) * 2018-05-17 2018-11-13 南京农业大学 A kind of production method of curcumin-ovalbumin compound anti-oxidation protein beverage
CN108976819A (en) * 2018-07-16 2018-12-11 广州大学 A kind of preparation method of soybean protein isolate-chitosan composite particle
CN109247425A (en) * 2018-08-22 2019-01-22 湖北工业大学 A kind of preparation method of the ovalbumin lotion with duplex shell structure
CN109453138A (en) * 2018-11-28 2019-03-12 江苏大学 A kind of load medicine albumin microparticle or nanoparticle and preparation method thereof
CN110710577A (en) * 2018-07-12 2020-01-21 华中农业大学 Preparation method of high-oil-loading-capacity emulsion rich in fibrous polysaccharide
CN111227161A (en) * 2020-01-09 2020-06-05 扬州大学 Ovalbumin-carvacrol nanoparticle and preparation method and antibacterial application thereof
CN111357971A (en) * 2020-04-23 2020-07-03 广州大学 Double-crosslinked pickering emulsion and preparation method and application thereof
CN111393671A (en) * 2020-03-27 2020-07-10 广州大学 Glycinin-chitosan composite gel and preparation method thereof

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005158B1 (en) * 2003-06-30 2006-02-28 University Of Florida Research Foundation, Inc. Methods of improving the properties of egg proteins
US20160038428A1 (en) * 2014-08-05 2016-02-11 Advanced Bionutrition Corp. Encapsulation of hydrophobic biologically active compounds
JP2016037461A (en) * 2014-08-06 2016-03-22 ユーハ味覚糖株式会社 Production method of nanoparticle which uses naturally occurring component as substrate
US20180134757A1 (en) * 2015-04-24 2018-05-17 Colgate-Palmolive Company Porous protein particles as carriers for actives
CN105601701A (en) * 2016-01-21 2016-05-25 中国农业大学 Protein-polyphenol covalent compound and preparation method and application thereof
CN108719999A (en) * 2018-05-07 2018-11-02 中国农业大学 A kind of preparation method and applications of protein-polyphenol-polysaccharide covalent compound
CN108783149A (en) * 2018-05-17 2018-11-13 南京农业大学 A kind of production method of curcumin-ovalbumin compound anti-oxidation protein beverage
CN110710577A (en) * 2018-07-12 2020-01-21 华中农业大学 Preparation method of high-oil-loading-capacity emulsion rich in fibrous polysaccharide
CN108976819A (en) * 2018-07-16 2018-12-11 广州大学 A kind of preparation method of soybean protein isolate-chitosan composite particle
CN109247425A (en) * 2018-08-22 2019-01-22 湖北工业大学 A kind of preparation method of the ovalbumin lotion with duplex shell structure
CN109453138A (en) * 2018-11-28 2019-03-12 江苏大学 A kind of load medicine albumin microparticle or nanoparticle and preparation method thereof
CN111227161A (en) * 2020-01-09 2020-06-05 扬州大学 Ovalbumin-carvacrol nanoparticle and preparation method and antibacterial application thereof
CN111393671A (en) * 2020-03-27 2020-07-10 广州大学 Glycinin-chitosan composite gel and preparation method thereof
CN111357971A (en) * 2020-04-23 2020-07-03 广州大学 Double-crosslinked pickering emulsion and preparation method and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHANG KEIFEI等: "Ferulic acid-ovalbumin protein nanoparticles: Structure and foaming behavior", FOOD RESEARCH INTERNATIONAL, vol. 136, pages 109311 *
史航: "卵清蛋白基复合载体的构建及其负载山奈酚/单宁酸的研究", 中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑, no. 12, pages 10 - 11 *

Also Published As

Publication number Publication date
CN113693225B (en) 2023-12-08

Similar Documents

Publication Publication Date Title
Hejjaji et al. Evaluation of the mucoadhesive properties of chitosan nanoparticles prepared using different chitosan to tripolyphosphate (CS: TPP) ratios
Fang et al. Effect of molecular weight and pH on the self-assembly microstructural and emulsification of amphiphilic sodium alginate colloid particles
Winuprasith et al. Microfibrillated cellulose from mangosteen (Garcinia mangostana L.) rind: Preparation, characterization, and evaluation as an emulsion stabilizer
Zhang et al. Improving the emulsifying property of gliadin nanoparticles as stabilizer of Pickering emulsions: Modification with sodium carboxymethyl cellulose
Yue et al. Effect of ultrasound assisted emulsification in the production of Pickering emulsion formulated with chitosan self-assembled particles: Stability, macro, and micro rheological properties
Wu et al. Effect of surface charge density of bacterial cellulose nanofibrils on the rheology property of O/W Pickering emulsions
Liu et al. Fabrication and characterization of Pickering emulsion gels stabilized by zein/pullulan complex colloidal particles
Song et al. Fabrication, Characterization, and Formation Mechanism of Zein–Gum Arabic Nanocomposites in Aqueous Ethanol Solution with a High Ethanol Content
Tang et al. In situ rapid conjugation of chitosan-gum Arabic coacervated complex with cinnamaldehyde in cinnamon essential oil to stabilize high internal phase Pickering emulsion
CN110511408A (en) LM/TA- chitosan hydrochloride composite nanometer particle, preparation method and application
Gao et al. Pomelo peel derived nanocellulose as Pickering stabilizers: Fabrication of Pickering emulsions and their potential as sustained-release delivery systems for lycopene
Zhang et al. Pickering emulsion stabilized by gliadin nanoparticles for astaxanthin delivery
Huang et al. Hydrophobically modified chitosan microgels stabilize high internal phase emulsions with high compliance
Xu et al. Soy protein isolate-citrus pectin-gallic acid ternary composite high internal phase Pickering emulsion for delivery of β-carotene: Physicochemical, structural and digestive properties
Kuang et al. Schiff base type casein-konjac glucomannan conjugates with improved stability and emulsifying properties via mild covalent cross-linking
Song et al. Fabrication of composite structures of lysozyme fibril–zein using antisolvent precipitation: Effects of blending and pH adjustment sequences
Wang et al. Nanocapsules formed by interactions between chondroitin sulfate and egg white protein for encapsulating hydrophilic ingredients
Cao et al. Tuning self-assembly of amphiphilic sodium alginate-decorated selenium nanoparticle surfactants for antioxidant Pickering emulsion
Wu et al. The gel mechanism and carrier quality of fibrous and granular whey protein self-assembly
Tang et al. Evaluation of pineapple peel cellulose nanocrystals/EGCG complexes for improving the stability of curcumin emulsion
Shi et al. Fabrication of compact zein-chondroitin sulfate nanocomplex by anti-solvent co-precipitation: Prevent degradation and regulate release of curcumin
CN114246326A (en) Preparation method and application of modified egg white protein
CN113693225B (en) Ovalbumin-ferulic acid-polysaccharide compound emulsion and preparation method and application thereof
CN110638754B (en) Oil-in-water emulsion using deamidated corn polypeptide as emulsifier and preparation method thereof
Zhong et al. Phycocyanin-chitosan complex stabilized emulsion: Preparation, characteristics, digestibility, and stability

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant